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Abstract: Background and objectives: Targeted therapy is widely used in the era of precision
medicine. Whether the sequence in which targeted therapy and chemotherapy are performed
matters, is however not known. We examined the impact of the sequential treatment of targeted
therapy and chemotherapy among advanced anaplastic lymphoma kinase (ALK), non-small cell
lung cancer (NSCLC) patients. Materials and Methods: Randomized controlled trials comparing the
use of ALK inhibitors with chemotherapy were included in this meta-analysis. We estimated the
hazard ratios (HRs) and 95% confidence intervals (CI), for progression-free survival (PFS) and overall
survival (OS) from a random effects model. Two-sided statistical tests were used to determine the
significance of these estimates. Results: In five eligible studies (1404 patients), ALK targeted therapy,
in comparison with chemotherapy, had a significantly higher PFS (HR = 0.48; 95% CI, 0.42–0.55),
but not significantly higher OS (HR = 0.88; 95% CI, 0.72–1.07). Crossover from chemotherapy to
ALK inhibitors was allowed after progression in all trials. The sensitivity analysis of the use of ALK
inhibitors as either the first- or second-line treatment, showed improvements in PFS but not in OS.
Conclusions: Our results indicate that using targeted therapy first improved PFS, but that the sequence
in which the treatments were performed did not cause a significant difference in overall survival.
Keywords: ALK inhibitor; chemotherapy; non-small-cell lung cancer; progression-free survival;
overall survival
1. Introduction
Lung cancer continues to be a leading cause of cancer-related deaths globally. Over the last decade,
advances in precision medicine for non-small-cell lung cancer (NSCLC) have spurred the development
of successful targeted therapies and have changed treatment guidelines. Anaplastic lymphoma
kinase (ALK)-positive (ALK+) NSCLC represents 3–5% of all NSCLC patients [1]. Traditionally,
chemotherapy has been the standard treatment before targeted therapies. It also might represent the
last resource after the failure of targeted therapy treatment. In a retrospective analysis of patients
with advanced ALK-positive NSCLC, crizotinib therapy is associated with an improved survival rate
in comparison with crizotinib-naïve controls [2]. In current studies, crossover is usually allowed for
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ethical considerations. Whether the delayed use of targeted therapy with ALK inhibitors causes harm
remains to be explored. In areas where ALK inhibitors needs to be self-paid, delayed targeted therapy
with ALK inhibitors might reduce the economic burden on patients and might not affect the overall
survival, if the sequence in which the therapies are performed is proven to make no difference.
This meta-analysis examines whether having targeted therapy as the first- or second-line of
therapy affects either progression-free survival (PFS) or overall survival (OS), by pooling evidence
from the currently available randomized controlled trials.
2. Methods
2.1. Study Selection
We conducted a review of MEDLINE (EBSCOhost) and PubMed up to 7 May 2018, and searched
the databases using the keywords “ALK” and “lung cancer”, without limitation. We also hand-searched
the relevant references. The potentially relevant studies were retrieved. For eligible studies that had
multiple reports, only the most recent or complete publication was included.
The goal of the analysis was to examine the effects of exposure to chemotherapy or ALK inhibitors
on progression-free survival and overall survival. Our analysis included only studies that fulfilled
these criteria: (1) randomized phase III prospective trials in lung cancer patients, and (2) randomization
in assigning patients to chemotherapy or ALK. Two reviewers (YCL and YLL) independently examined
the title and the abstract of the publications identified by the search strategy. The full texts of
all the potentially relevant publications were retrieved. A five-point Jadad ranking system [3] on
randomization, double-blinding, and withdrawals was used to assess the quality of the study.
2.2. Data Extraction
We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA,
http://www.prisma-statement.org) statement for data extraction. The information that was extracted
from each study included the publication year, the name of the first author, the trial type, the patient
number, the median PFS, and the median OS.
2.3. Statistical Analysis
The heterogeneity among the trials was assessed using Cochrane’s Q statistic, and the degree
of heterogeneity was quantified by the I2 statistic, which estimated the total percentage of variation
across studies that was due to heterogeneity rather than to chance. A random-effects model was used
to obtain a summary of the hazard ratios (HRs) and 95% confidence intervals (CI). The statistical
significance was set at the two-sided p-value of <0.05. We used the Stata software (version 12.0,
College Station, TX, USA) to perform all of the statistical analyses.
3. Results
Search Results
From a review of 4225 total titles or abstracts, 27 full articles were retrieved. Of these, five
articles satisfied the inclusion criteria [1,4–7] and were therefore included in the analysis, see Figure 1.
The reasons for excluding the other 21 articles were that they had a nonrandomized design (two
articles), that they were a secondary publication (two articles), that the study was single-arm only
(three articles), that their analysis was retrospective (two articles), that economics was the main focus
of the article (one article), and that they were review articles (12 articles), see Figure 1. Table 1 displays
the characteristics of the five studies.
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Figure 1. Selection of studies in the meta-analysis.
In total, the five studies included 1404 patients, 721 of which were assigned to ALK inhibitors,
while 683 were assigned to control arms, at random. The significance of the imbalance between the
two groups was due to the unbalanced design, introduced by Novello et al. [4], where patients were
randomized at a ratio of 2:1 to receive alectinib or chemotherapy. Cross-over after chemotherapy failure
was allowed in all studies, but the inverse was not mentioned. The median age of the patients was 55.
The brain metastasis status was balanced among all the studies. The other clinical characteristics of the
patients are summarized in Table 1. All of the studies were open-label, phase 3 trials, so two points
were deducted for not being double-blinded on the five-point Jadad scale, which was used to assess
the quality of the studies, as seen in Table 2. Only two of the studies scored 3, two studies scored 2,
and one study scored 1.
In comparison with chemotherapy, treatment with ALK inhibitors was associated with a
significant reduction in PFS (HR = 0.48, 95% CI: 0.42–0.55), as seen in Figure 2, but not in OS (HR = 0.88,
95% CI: 0.72–1.07), as seen in Figure 3. No significant heterogeneity was found. In a sensitivity analysis,
using the data for first-line ALK targeted therapy from two trials [1,5], the pooled HR for PFS was
0.50 (95% CI, 0.41–0.60) and 0.77 (95% CI, 0.59–1.02) for OS. In the three trials that had data on ALK
targeted therapy as the second-line treatment [4,6,7], the pooled HR was 0.47 (95% CI, 0.39–0.57) for
PFS and 1.00 (95% CI, 0.76–1.31) for OS. Again, no significant heterogeneity was observed.
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Table 1. Characteristics of the clinical trials.
Trials, Year Setting Regiment Patient No. Age(Median)
Cross-Over
(%)
Initial Brain
Meta (%)
Follow-Up Median
Time (m) PFS (m) OS (m)
PROFILE 1014, 2014 [1] First-line Crizotinib vs.PEM + cisplatin 172 171 52 54 Yes (70%) 26 27 17.4 16.7 10.9 7 17.4 16.7
ASCEND-4, 2017 [6] First-line Ceritinib vs. PEM+ platinum 189 187 55 54
Yes
((105/187)56%) 31 33 NA NA 16.6 8.1 NR 26.2
PROFILE 1007, 2013 [5] Second-line Crizotinib vs.PEM or TXT 173 174 51 49
Yes
((112/174)64%) 35 34 12.2 12.1 7.7 3.0 NR NR
ALUR, 2018 [4] Two prior lines, crizotinib,platinum-based doublet
Alectinib vs. PEM
or TXT
72 35 (2:1
block) 55.5 59 Yes (70.6%) 65.3 74.3 6.5 5.8 7.1 1.6 12.6 NR
ASCEND-5, 2017 [7] 1 or 2 chemotherapy, andcrizotinib resistance
Ceritinib vs. PEM
or TXT 115 116 54 54 Yes (64.7%) 57 59 19.7 5.4 1.6 18.1 20.1
In this table, NR indicates not reached; PEM indicates pemetred; and TXT indicates docetaxel. C/T indicates chemotherapy.
Table 2. Jadad scale analysis of controlled trials.
Trials, Year
Was the Study
Described as
Randomized?
Method to Generate the
Sequence of Randomization
was Described and
Appropriate
Was the Study
Described as a
Double Blind?
Method of Double
Blinding was
Described and
Appropriate
Was There a
Description of
Withdrawal and
Dropouts?
Score
PROFILE 1014, 2014 [1] * - - - * 2
ASCEND-4, 2017 [6] * * - - * 3
PROFILE 1007, 2013 [5] * - - - * 2
ALUR, 2018 [4] * - - - (note) - 1
ASCEND-5, 2017 [7] * * - - (note) * 3
Note: Open-label, blinded independent review committee.
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ceritinib group who had no brain metastases at baseline progressed, with most of the progressions
outside of the brain (85%). In the chemotherapy group, among those without brain metastasis at
baseline, 68% progressed. Among the patients with progression, 10% had intracranial progression
only, 82% had extracranial progression only, and 8% had both. Determining whether the patients with
brain metastasis survived less or had a poorer quality of life needs further investigation.
Multiple variants of the echinoderm microtubule-associated protein-like 4 (EML4)-ALK have been
reported on, with V1, V2 and V3a/b as the most common. The mutations result in the constitutive
ligand-independent activation of the downstream Ras/mitogen-activated protein kinase, the
(MAPK)/extracellular signal regulated kinase (ERK), the PI3K/AKT and Janus kinase 3 (JAK3)/signal
transducer and activator of transcription 3 (STAT3) [12]. The mechanisms of resistance to crizotinib
include the ALK-independent mechanism (50%), ALK mutation (31%), ALK amplification (13%),
or both ALK mutation and amplification (6%) [13]. Second-generation inhibitors (e.g., ceritinib,
alecitinb and brigatinib) are generally effective, whether crizotinib-resistant or not, but cause a higher
frequency of one mutation, ALKG1202R [11]. We do not know if there is a tradeoff between using
second-generation inhibitors, causing more ALKG1202R mutations, and decreasing the use crizotinib,
which might affect the overall survival. Third-generation lorlatinib is active against the ALK resistance
mutations that developed against second-generation ALK inhibitors [11]. However, cell lines without
ALK resistance mutations are resistant to lorlatinib [11]. Should we select targeted therapy, using the
same rule as antibiotic treatment, by treating resistant bacteria at very low antibiotic concentrations
with lower potency, and save the more potent inhibitors as the last resort? If this is true, we should use
first-generation ALK inhibitors first. Or, alternatively, should the more potent drugs be used in order
to prolong overall survival?
This study has some limitations. Among the five studies, three have not yet reported more mature
data on OS. Also, we grouped the first-, second- and third-line studies together. Our results have
shown that at least first-line treatment of ALK-positive NSCLC with chemotherapy, as the Taiwan
national health insurance policy dictates, would not decrease OS as long as targeted therapy with ALK
inhibitors is available as the second-line treatment.
5. Conclusions
The choice of the first-line treatment for ALK-positive, non-small cell lung cancer needs to take
into account cost–benefit considerations and the patient-reported quality of life, as the treatment
sequence did not cause a significant difference in overall survival.
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